The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

Consumer Electronics Show CES the world premier tech show concluded in the US city of Las Vegas on Friday showcasing latest advancemen ...

The agency wants applicants to demystify their algorithms and provide specific details about what the models do, how they’re ...

Scientists have collected troves of DNA and microscopic imaging data from human cells—and now they have a tool that might ...

Stay updated on the volatile share price of Recursion, a biotech company with a maturing pipeline and potential for growth ...

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

(OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer's disease, announced its ...

A middle school student in Chicago made headlines by uncovering a remarkable medical breakthrough hidden in a surprising ...

Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...